Nymox Corporation
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) (NCT01846793) | Nymox Corporation | 2013-04-01 |
| Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer (NCT01620515) | Nymox Corporation | 2012-02-21 |
| Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (NCT01438775) | Nymox Corporation | 2011-09-01 |
| Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018 (NCT00945490) | Nymox Corporation | 2009-05-01 |
| Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (NCT00918983) | Nymox Corporation | 2009-04-01 |
| Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate) (NCT00759135) | Nymox Corporation | 2007-05-01 |
Track Nymox Corporation automatically
Every clearance here is in the API, with alerts when new ones post.